The significant developments in the treatment of chronic lymphocytic leukaemia (CLL) in recent years demand an update of the British Committee for Standards in Haematology Guidelines for CLL (Oscier et al, 2012) with a focus on therapy. The guidance in this document refers to treatment outside clinical trials. However, the basic principle remains that, wherever possible, treatment of patients with CLL should be delivered within the context of a clinical trial.
Declaration of Interests
The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.